Basilea Pharmaceutica AG – LSE:0QNA.L
Basilea Pharmaceutica AG stock price today
Basilea Pharmaceutica AG stock price monthly change
Basilea Pharmaceutica AG stock price quarterly change
Basilea Pharmaceutica AG stock price yearly change
Basilea Pharmaceutica AG key metrics
Market Cap | 501.21M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | 1.89 |
Revenue | 305.39M |
EBITDA | 42.32M |
Income | 22.59M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | 13.86% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBasilea Pharmaceutica AG stock price history
Basilea Pharmaceutica AG stock forecast
Basilea Pharmaceutica AG financial statements
| Jun 2022 | 58.64M | -12.20M | -20.82% |
|---|---|---|---|
| Dec 2022 | 89.11M | 24.35M | 27.33% |
| Jun 2023 | 84.90M | 31.84M | 37.5% |
| Dec 2023 | 72.72M | -21.38M | -29.41% |
| 2025 | 191.80M | 23.32M | 12.16% |
|---|---|---|---|
| 2026 | 223.49M | 44.72M | 20.01% |
| 2027 | 223.31M | 73.04M | 32.71% |
| 2028 | 204.34M | 79.65M | 38.98% |
Analysts Price target
Financials & Ratios estimates
| Sep 2022 | 220848000 | 241.56M | 109.38% |
|---|---|---|---|
| Dec 2022 | 220848000 | 241.56M | 109.38% |
| Jun 2023 | 230034000 | 215.04M | 93.48% |
| Dec 2023 | 173289000 | 183.29M | 105.77% |
| Jun 2022 | 148.99K | -2.31M | -6.76M |
|---|---|---|---|
| Dec 2022 | 6.90M | 93.96M | -38.48M |
| Jun 2023 | 21.86M | -389K | -17.08M |
| Dec 2023 | -7.61M | -645K | -40.22M |
Basilea Pharmaceutica AG alternative data
| Aug 2023 | 141 |
|---|---|
| Sep 2023 | 143 |
| Oct 2023 | 143 |
| Nov 2023 | 143 |
| Dec 2023 | 143 |
| Jan 2024 | 143 |
| Feb 2024 | 143 |
| Mar 2024 | 147 |
| Apr 2024 | 147 |
| May 2024 | 147 |
| Jun 2024 | 147 |
| Jul 2024 | 147 |
Basilea Pharmaceutica AG other data
| Insider | Compensation |
|---|---|
Mr. David Veitch (1965) Chief Executive Officer | $1,040,000 |
Mr. Adesh Kaul Chief Financial Officer | |
Dr. Gerrit Hauck Chief Technology Officer | |
Dr. Laurenz Kellenberger Chief Scientific Officer | |
Dr. Marc Engelhardt Chief Medical Officer | |
Dr. Peer Nils Schröder Head of Corporation Communications & Investor Relations | |
Mr. Damian Heller Gen. Counsel & Corporation Sec. | |
Ms. Ursula Eberhardt Head of Global HR | |
Mr. Lutz Wevelsiep Head of Regulatory Affairs | |
Mr. Dietrich Stüber Head of Internal Services |
-
What's the price of Basilea Pharmaceutica AG stock today?
One share of Basilea Pharmaceutica AG stock can currently be purchased for approximately $41.7.
-
When is Basilea Pharmaceutica AG's next earnings date?
Unfortunately, Basilea Pharmaceutica AG's (0QNA.L) next earnings date is currently unknown.
-
Does Basilea Pharmaceutica AG pay dividends?
No, Basilea Pharmaceutica AG does not pay dividends.
-
How much money does Basilea Pharmaceutica AG make?
Basilea Pharmaceutica AG has a market capitalization of 501.21M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 6.68% to 157.63M US dollars.
-
What is Basilea Pharmaceutica AG's stock symbol?
Basilea Pharmaceutica AG is traded on the LSE under the ticker symbol "0QNA.L".
-
What is Basilea Pharmaceutica AG's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Basilea Pharmaceutica AG?
Shares of Basilea Pharmaceutica AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Basilea Pharmaceutica AG's key executives?
Basilea Pharmaceutica AG's management team includes the following people:
- Mr. David Veitch Chief Executive Officer(age: 60, pay: $1,040,000)
- Mr. Adesh Kaul Chief Financial Officer
- Dr. Gerrit Hauck Chief Technology Officer
- Dr. Laurenz Kellenberger Chief Scientific Officer
- Dr. Marc Engelhardt Chief Medical Officer
- Dr. Peer Nils Schröder Head of Corporation Communications & Investor Relations
- Mr. Damian Heller Gen. Counsel & Corporation Sec.
- Ms. Ursula Eberhardt Head of Global HR
- Mr. Lutz Wevelsiep Head of Regulatory Affairs
- Mr. Dietrich Stüber Head of Internal Services
-
How many employees does Basilea Pharmaceutica AG have?
As Jul 2024, Basilea Pharmaceutica AG employs 147 workers.
-
When Basilea Pharmaceutica AG went public?
Basilea Pharmaceutica AG is publicly traded company for more then 11 years since IPO on 7 Mar 2014.
-
What is Basilea Pharmaceutica AG's official website?
The official website for Basilea Pharmaceutica AG is basilea.com.
-
How can i contact Basilea Pharmaceutica AG?
Basilea Pharmaceutica AG can be reached via phone at +41 61 606 11 11.
Basilea Pharmaceutica AG company profile:
Basilea Pharmaceutica AG
basilea.comLSE
156
Medical - Pharmaceuticals
Healthcare
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
Basel, 4058
:
ISIN: CH0011432447
:
